Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells
Open Access
- 1 February 2005
- Vol. 60 (2), 144-152
- https://doi.org/10.1136/thx.2004.025692
Abstract
Background: A common pathological feature of chronic inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) is mucus hypersecretion. MUC5AC is the predominant mucin gene expressed in healthy airways and is increased in asthmatic and COPD patients. Recent clinical trials indicate that phosphodiesterase type 4 (PDE4) inhibitors may have therapeutic value for COPD and asthma. However, their direct effects on mucin expression have been scarcely investigated. Methods: MUC5AC mRNA and protein expression were examined in cultured human airway epithelial cells (A549) and in human isolated bronchial tissue stimulated with epidermal growth factor (EGF; 25 ng/ml). MUC5AC mRNA was measured by real time RT-PCR and MUC5AC protein by ELISA (cell lysates and tissue homogenates), Western blotting (tissue homogenates) and immunohistochemistry. Results: EGF increased MUC5AC mRNA and protein expression in A549 cells. PDE4 inhibitors produced a concentration dependent inhibition of the EGF induced MUC5AC mRNA and protein expression with potency values (−log IC50): roflumilast (∼7.5) > rolipram (∼6.5) > cilomilast (∼5.5). Roflumilast also inhibited the EGF induced expression of phosphotyrosine proteins, EGF receptor, and phospho-p38- and p44/42-MAPK measured by Western blot analysis in A549 cells. In human isolated bronchus, EGF induced MUC5AC mRNA and protein expression was inhibited by roflumilast (1 μM) as well as the MUC5AC positive staining shown by immunohistochemistry. Conclusion: Selective PDE4 inhibition is effective in decreasing EGF induced MUC5AC expression in human airway epithelial cells. This effect may contribute to the clinical efficacy of this new drug category in mucus hypersecretory diseases.Keywords
This publication has 30 references indexed in Scilit:
- Mechanisms by Which Gram‐Positive Bacteria and Tobacco Smoke Stimulate Mucin Induction through the Epidermal Growth Factor Receptor (EGFR)Novartis Foundation symposium, 2002
- Pseudomonas aeruginosa induces MUC5AC production via epidermal growth factor receptorEuropean Respiratory Journal, 2002
- Expression of c-erbB receptors and ligands in the bronchial epithelium of asthmatic subjectsJournal of Allergy and Clinical Immunology, 2002
- Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells.2001
- Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.2001
- Relationship of Epidermal Growth Factor Receptors to Goblet Cell Production in Human BronchiAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Inhibition of Phosphodiesterase 4 Attenuates Airway Hyperresponsiveness and Airway Inflammation in a Model of Secondary Allergen ChallengeAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Sub‐family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP‐specific phosphodiesterasesBritish Journal of Pharmacology, 2000
- Oxidative Stress Causes Mucin Synthesis Via Transactivation of Epidermal Growth Factor Receptor: Role of NeutrophilsThe Journal of Immunology, 2000
- M1/MUC5AC mucin released by human airways in vitro.European Respiratory Journal, 1999